Merck: REMICADE Win, Settlement on Vioxx
REMICADE, made by Merck (NYSE:MRK), has been used in the treatment of inflammatory bowel disease for more than 12 years in the EU. Now, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the use of REMICADE in the treatment of severely active ulcerative colitis in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, according to Merck. REMICADE will be the first and only biologic therapy approved in the EU for the treatment of pediatric ulcerative colitis, upon receipt of the corresponding Commission Decision.
Merck, denying any wrongdoing, will pay up to $36.5M to settle all of its Vioxx lawsuits in Canada, with the minimum payment expected to be no less than $21.6M, according to the Associated Press.